4-乙基4-(碘甲基)哌啶-1,4-二羧酸-1-叔丁酯 | 213013-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-乙基4-(碘甲基)哌啶-1,4-二羧酸-1-叔丁酯
• 中文别名: 4-（碘甲基）哌啶-4-羧酸乙酯，N-BOC保护
• 英文名称: 1-(tert-butyl) 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate
• 英文别名: 1-tert-Butyl 4-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate；1-O-tert-butyl 4-O-ethyl 4-(iodomethyl)piperidine-1,4-dicarboxylate
• CAS: 213013-98-0
• 化学式: C₁₄H₂₄INO₄
• 分子量: 397.253
• InChiKey: FKZDQBQVWKAEHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-乙基4-(碘甲基)哌啶-1,4-二羧酸-1-叔丁酯 在 potassium carbonate 、 caesium carbonate 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 氘代二甲亚砜 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester
  参考文献：
  名称：

  Identification of potent and selective TACE inhibitors via the S1 pocket

  摘要：

  By focusing on the P1 portion of the piperidine beta-sulfone ligands we identified a motif that induces selectivity and resulted in a series of TACE inhibitors that demonstrated excellent in vitro potency against isolated TACE enzyme and excellent selectivity over MMPs 1, 2, 9, 13, and 14.

  DOI：

  10.1016/j.bmcl.2006.10.004
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 13.0h， 生成 4-乙基4-(碘甲基)哌啶-1,4-二羧酸-1-叔丁酯
  参考文献：
  名称：

  Design and synthesis of butynyloxyphenyl β-sulfone piperidine hydroxamates as TACE inhibitors

  摘要：

  A series of butynyloxyphenyl P-sulfone piperidine hydroxamate TACE inhibitors was designed and synthesized. The resulting structure-activity relationship and MMP selectivity of the series were examined. Of the compounds investigated, 17s has excellent in vitro potency against isolated TACE enzyme, shows good selectivity over MMP-1, -2, -7, -8, -9, -13, and -14, and oral activity in an in vivo mouse model of TNF-alpha production. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.026

文献信息

• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：Novartis AG

  公开号：US20210115065A1

  公开（公告）日：2021-04-22

  The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

  本发明提供了化合物(Ia)的结构或其药学上可接受的盐； 一种制造本发明化合物的方法，固体形式，药理活性剂的组合，药物组合物以及使用这些化合物和固体形式来治疗或预防寄生虫病，例如疟疾的方法。
• Amidine compounds
  申请人：Japan Tobacco Inc.

  公开号：US06562828B1

  公开（公告）日：2003-05-13

  A compound of the formula [I] wherein R1, R2 and R3 are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention, a salt thereof and a prodrug thereof are useful as factor Xa inhibitor and blood coagulation inhibitor, and are useful for the prophylaxis and/or treatment of diseases caused by blood coagulation or thrombus.

  其中R1、R2和R3相同或不同，且每个都是氢原子，其中每个符号如规范中定义，其盐或前药。本发明的化合物及其盐和前药可用作因子Xa抑制剂和抗凝血剂，对于预防和/或治疗由血液凝固或血栓引起的疾病有用。
• Synthesis and Structure−Activity Relationships of Novel Selective Factor Xa Inhibitors with a Tetrahydroisoquinoline Ring
  作者：Hiroshi Ueno、Katsuyuki Yokota、Jun-ichi Hoshi、Katsutaka Yasue、Mikio Hayashi、Yasunori Hase、Itsuo Uchida、Kazuo Aisaka、Susumu Katoh、Hidetsura Cho

  DOI：10.1021/jm058160e

  日期：2005.5.1

  A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds 1 and 2 exhibited potent inhibitory activity against factor Xa (FXa) and good selectivity with respect to other serine proteases (thrombin, plasmin, and trypsin). In addition, compound 2 exhibited potent anti-FXa activity after intravenous and oral administration

  设计并合成了一系列新颖的2,7-二取代的四氢异喹啉衍生物。在这些衍生物中，化合物1和2对Xa因子（FXa）表现出有效的抑制活性，并且对其他丝氨酸蛋白酶（凝血酶，纤溶酶和胰蛋白酶）具有良好的选择性。此外，化合物2在食蟹猴静脉和口服给药后均显示出有效的抗FXa活性，在0.1、0.3和1 mg kg（-1）h（-1）的大鼠模型中显示出剂量依赖性的抗血栓形成作用。静脉血栓形成，并以0.1 mg kg（-1）h（-1）的剂量显着减少了大脑中动脉闭塞模型中脑梗塞的大小。这些结果表明，化合物2（JTV-803）可能同时用作静脉和动脉抗血栓形成剂。
• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06358980B1

  公开（公告）日：2002-03-19

  Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

  该式化合物有助于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染。
• Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria
  作者：Benjamin R. Taft、Fumiaki Yokokawa、Tom Kirrane、Anne-Catherine Mata、Richard Huang、Nicole Blaquiere、Grace Waldron、Bin Zou、Oliver Simon、Subramanyam Vankadara、Wai Ling Chan、Mei Ding、Sandra Sim、Judith Straimer、Armand Guiguemde、Suresh B. Lakshminarayana、Jay Prakash Jain、Christophe Bodenreider、Christopher Thompson、Christian Lanshoeft、Wei Shu、Eric Fang、Jafri Qumber、Katherine Chan、Luying Pei、Yen-Liang Chen、Hanna Schulz、Jessie Lim、Siti Nurdiana Abas、Xiaoman Ang、Yugang Liu、Iñigo Angulo-Barturen、María Belén Jiménez-Díaz、Francisco Javier Gamo、Benigno Crespo-Fernandez、Philip J. Rosenthal、Roland A. Cooper、Patrick Tumwebaze、Anna Caroline Campos Aguiar、Brice Campo、Simon Campbell、Jürgen Wagner、Thierry T. Diagana、Christopher Sarko

  DOI：10.1021/acs.jmedchem.1c01995

  日期：2022.3.10

  A series of 5-aryl-2-amino-imidazothiadiazole (ITD) derivatives were identified by a phenotype-based high-throughput screening using a blood stage Plasmodium falciparum (Pf) growth inhibition assay. A lead optimization program focused on improving antiplasmodium potency, selectivity against human kinases, and absorption, distribution, metabolism, excretion, and toxicity properties and extended pharmacological

  使用血液分期恶性疟原虫( Pf ) 生长抑制试验，通过基于表型的高通量筛选鉴定了一系列 5-芳基-2-氨基-咪唑并噻二唑( ITD ) 衍生物。一项主要优化计划侧重于提高抗疟原虫效力、对人类激酶的选择性以及吸收、分布、代谢、排泄和毒性特性以及扩展的药理学特征，最终鉴定出INE963 ( 1 )，证明了对Pf 3D7的有效细胞活性。 EC 50 = 0.006 μM）并达到“青蒿素样”杀灭动力学在体外，寄生虫清除时间<24小时。单剂量 30 mg/kg 在Pf人源化严重联合免疫缺陷小鼠模型中完全治愈。INE963 ( 1 ) 在药物选择研究中还表现出很高的抗药性屏障和跨物种的长半衰期 ( T 1/2 )。这些特性表明INE963 ( 1 )具有巨大的潜力，可以通过短剂量方案为简单的疟疾提供治愈性疗法。由于这些原因，INE963 ( 1 ) 通过 GLP 毒理学研究取得了进展，目前正在进行 Ph1